A landscape of response to drug combinations in non-small cell lung cancer
Open Access
- 28 June 2023
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-19
Abstract
Combination of anti-cancer drugs is broadly seen as way to overcome the often-limited efficacy of single agents. The design and testing of combinations are however very challenging. Here we present a uniquely large dataset screening over 5000 targeted agent combinations across 81 non-small cell lung cancer cell lines. Our analysis reveals a profound heterogeneity of response across the tumor models. Notably, combinations very rarely result in a strong gain in efficacy over the range of response observable with single agents. Importantly, gain of activity over single agents is more often seen when co-targeting functionally proximal genes, offering a strategy for designing more efficient combinations. Because combinatorial effect is strongly context specific, tumor specificity should be achievable. The resource provided, together with an additional validation screen sheds light on major challenges and opportunities in building efficacious combinations against cancer and provides an opportunity for training computational models for synergy prediction.Keywords
Funding Information
- Wellcome Trust (102696)
This publication has 89 references indexed in Scilit:
- Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibitionCancer Cell International, 2012
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 MutationsNew England Journal of Medicine, 2012
- Comprehensive genomic characterization of squamous cell lung cancersNature, 2012
- Systematic identification of genomic markers of drug sensitivity in cancer cellsNature, 2012
- Feedback regulation of EGFR signalling: decision making by early and delayed loopsNature Reviews Molecular Cell Biology, 2011
- Use of Antifungal Combination Therapy: Agents, Order, and TimingCurrent Fungal Infection Reports, 2010
- Principles of Cancer Therapy: Oncogene and Non-oncogene AddictionCell, 2009
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNature Medicine, 2008
- The Concept of Synthetic Lethality in the Context of Anticancer TherapyNature Reviews Cancer, 2005
- KEGG: Kyoto Encyclopedia of Genes and GenomesNucleic Acids Research, 2000